SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 4403-4412. Prepublished online as a Blood First Edition Paper on February 6, 2008; DOI 10.1182/blood-2007-06-097287. This Article Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-06-097287v1 111/8/4403    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hori, T. Articles by Kokai, Y. Search for Related Content PubMed PubMed Citation Articles by Hori, T. Articles by Kokai, Y. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 22, 2007 Accepted January 31, 2008 CCL8 is a potential molecular candidate for the diagnosis of graft versus host disease Tsukasa Hori, Yasuyoshi Naishiro, Hitoshi Sohma, Nobuhiro Suzuki, Naoki Hatakeyama, Masaki Yamamoto, Tomoko Sonoda, Yuka Mizue, Kohzoh Imai, Hiroyuki Tsutsumi, and Yasuo Kokai* Department of Biomedical Engineering, Sapporo Medical University, Sapporo, Japan Department of Pediatrics, Sapporo Medical University, Sapporo, Japan Department of Public Health, Sapporo Medical University, Sapporo, Japan Department of Immunodiagnositics, Sapporo ImmunoDiagnostics Laboratory, Sapporo, Japan President, Sapporo Medical Univesity, Sapporo, Japan * Corresponding author; email: kokai{at}sapmed.ac.jp. Although graft-versus-host disease (GVHD) is a life- threatening complication of hematopoietic stem cell transplantation (HSCT), its current diagnosis mainly depends on clinical manifestations and invasive biopsies. Specific biomarkers for GVHD would facilitate early and accurate recognition of this grave condition. Using proteomics, we screened for plasma proteins specific for GVHD in a mouse model. One peak with 8,972 m/z retained a discriminatory value in two diagnostic groups (GVHD and normal controls) with increased expression in the disease, decreased expression during cyclosporin A treatment and was barely detectable in syngeneic transplantation. Purification and mass analysis identified this molecule as CCL8, a member of a large chemokine family. In human samples, the serum concentration of CCL8 correlated closely with GVHD severity. All non-GVHD samples contained less than 48 pg/mL (mean+/-SE: 22.5+/-5.5, range: 12.6-48.0 pg/mL, n=7). In sharp contrast, CCL8 was highly upregulated in GVHD sera ranging from 52.0 to 333.6 pg/mL (mean+/-SE: 165.0 +/-39.8 pg/mL, n=7). Strikingly, two patients with severe fatal GVHD had extremely high levels of CCL8, i.e. 333.6 and 290.4 pg/mL. CCL8 is a promising specific serum marker for the early and accurate diagnosis of GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020